Coral Laboratories Ltd
Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]
- Market Cap ₹ 179 Cr.
- Current Price ₹ 502
- High / Low ₹ 625 / 360
- Stock P/E 11.1
- Book Value ₹ 585
- Dividend Yield 0.30 %
- ROCE 11.0 %
- ROE 7.88 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.86 times its book value
Cons
- The company has delivered a poor sales growth of -2.31% over past five years.
- Company has a low return on equity of 10.1% over last 3 years.
- Earnings include an other income of Rs.10.2 Cr.
- Working capital days have increased from 217 days to 328 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59 | 77 | 95 | 92 | 91 | 71 | 97 | 76 | 78 | 84 | 115 | 86 | |
| 47 | 60 | 72 | 77 | 79 | 65 | 81 | 67 | 74 | 67 | 89 | 71 | |
| Operating Profit | 12 | 16 | 23 | 15 | 12 | 5 | 16 | 8 | 4 | 16 | 26 | 15 |
| OPM % | 21% | 21% | 24% | 17% | 14% | 8% | 16% | 11% | 5% | 19% | 23% | 18% |
| 3 | 3 | 3 | 4 | 5 | 6 | 4 | 6 | 7 | 6 | 8 | 10 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 12 | 17 | 25 | 18 | 16 | 9 | 18 | 12 | 8 | 21 | 32 | 23 |
| Tax % | 22% | 29% | 34% | 31% | 34% | 22% | 23% | 24% | 22% | 24% | 26% | 29% |
| 10 | 12 | 16 | 12 | 10 | 7 | 14 | 9 | 6 | 16 | 24 | 16 | |
| EPS in Rs | 26.79 | 34.71 | 45.63 | 34.85 | 28.61 | 19.96 | 37.93 | 25.33 | 18.05 | 44.20 | 67.63 | 45.85 |
| Dividend Payout % | 9% | 9% | 11% | 6% | 7% | 0% | 0% | 0% | 0% | 0% | 0% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -2% |
| 3 Years: | 3% |
| TTM: | -25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 36% |
| TTM: | -35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 1% |
| 3 Years: | 27% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 56 | 67 | 106 | 113 | 110 | 112 | 133 | 152 | 151 | 174 | 198 | 206 |
| 1 | 0 | 2 | 2 | 1 | 6 | 6 | 6 | 0 | 0 | 4 | 4 | |
| 12 | 19 | 20 | 22 | 21 | 23 | 25 | 28 | 20 | 28 | 25 | 27 | |
| Total Liabilities | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 | 241 |
| 19 | 18 | 18 | 22 | 23 | 23 | 21 | 24 | 25 | 24 | 23 | 44 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 |
| Investments | 1 | 5 | 39 | 45 | 28 | 25 | 33 | 46 | 41 | 50 | 52 | 46 |
| 52 | 67 | 74 | 73 | 84 | 97 | 112 | 118 | 108 | 132 | 152 | 150 | |
| Total Assets | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 | 241 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 5 | 11 | 13 | -1 | -4 | 1 | 6 | 13 | -5 | -1 | 16 | |
| -0 | -3 | -10 | -13 | 3 | -2 | -0 | -6 | -3 | 1 | -0 | -18 | |
| -0 | -0 | 0 | -3 | -1 | 4 | 0 | 0 | -6 | 0 | 3 | 0 | |
| Net Cash Flow | -0 | 2 | 1 | -2 | 1 | -2 | 1 | 0 | 4 | -4 | 1 | -2 |
| Free Cash Flow | -1 | 4 | 9 | 9 | -4 | -5 | -0 | 1 | 11 | -6 | -4 | -5 |
| CFO/OP | 30% | 70% | 85% | 124% | 31% | -59% | 28% | 127% | 383% | -4% | 23% | 150% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 152 | 132 | 117 | 125 | 122 | 178 | 148 | 184 | 109 | 123 | 107 | 125 |
| Inventory Days | 110 | 110 | 155 | 120 | 116 | 176 | 158 | 169 | 100 | 149 | 68 | 211 |
| Days Payable | 66 | 80 | 75 | 87 | 91 | 129 | 108 | 81 | 34 | 130 | 46 | 103 |
| Cash Conversion Cycle | 196 | 162 | 197 | 157 | 146 | 225 | 198 | 272 | 176 | 142 | 129 | 233 |
| Working Capital Days | 194 | 179 | 164 | 161 | 171 | 241 | 178 | 222 | 221 | 183 | 140 | 328 |
| ROCE % | 22% | 27% | 28% | 16% | 13% | 8% | 13% | 7% | 5% | 13% | 17% | 11% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Share of Revenue % |
|
|||||||||||
| Number of Manufacturing Plants Number |
||||||||||||
| Number of Permanent Employees Number |
||||||||||||
| Electricity Consumption (Utility Indirect Volume) Lakh Units |
||||||||||||
Extracted by Screener AI
Documents
Announcements
- Corporate Action-Board approves Dividend 30 May
-
Appointment Of Internal Auditor
30 May - Coral Laboratories appointed S.K. Doshi & Associates as internal auditor for FY 2026-27 effective May 30, 2026.
-
Appointment Of Cost Auditor
30 May - M/s Aatish Dhatrak & Associates appointed cost auditor for FY 2026-27 effective May 30, 2026.
-
Announcement under Regulation 30 (LODR)-Dividend Updates
30 May - Board approved FY26 audited results, recommended ₹2 final dividend, and appointed internal and cost auditors.
-
Results For The Financial Year Ended On March 31, 2026
30 May - Board approved FY26 audited results, recommended ₹2 final dividend, and appointed internal and cost auditors.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
CLL is an ISO 9001:2008 certified manufacturer and exporter of pharmaceutical formulations like tablets, capsules, liquid, and topical preparations. It focuses on generics, troubleshooting existing products, and patent noninfringing products for emerging markets.